• Alpha Cognition flagged new clinical and real-world findings on its Alzheimer’s drug ZUNVEYL for upcoming medical meetings in late 2026.
• Data will be presented at the ASCP Annual Meeting on Oct. 29–Nov. 1, 2026, then at the NEI Fall Congress on Nov. 5–8, 2026.
• Analyses indicate ZUNVEYL use in long-term care settings was associated with favorable cognitive, functional, behavioral, sleep, tolerability outcomes.
• Additional readouts track real-world treatment patterns, including switching from other acetylcholinesterase inhibitors, with changes in psychotropic medication use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006477510) on October 06, 2026, and is solely responsible for the information contained therein.